BioVaxys Technology Corp CEO James Passin tells Proactive it has confirmed its first clinical site for its Phase I ovarian cancer vaccine trial.
The study on BVX-0918, the company's autologous haptenized tumor cell vaccine for late-stage ovarian cancer, will take place at Hospices Civils de Lyon in France, according to a company statement.
HCL has also agreed to supply BioVaxys with surgically debulked tumors from Stage III/Stage IV ovarian cancer patients undergoing treatment at the hospital to allow the company to perform manufacturing tests.
